Craig-Hallum downgraded Miromatrix Medical (MIRO) to Hold from Buy with a $3.25 price target after United Therapeutics (UTHR) agreed to acquire Miromatrix for a purchase price of $3.25 per share in cash at closing and an additional $1.75 per share in cash upon the achievement of a clinical development milestone related to Miromatrix’s fully-implantable manufactured kidney product known as mirokidney by December 31, 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MIRO:
- United Therapeutics to Acquire Miromatrix Medical
- United Therapeutics to acquire Miromatrix Medical
- Miromatrix to Present at the 2023 ISODP Organ Donation Congress
- Miromatrix CEO Jeff Ross to Present at the 2023 Cell & Gene Meeting on the Mesa
- Miromatrix Announces Participation in H.C. Wainwright Global Investment Conference
